Welcome, this website is intended for international healthcare professionals with an interest in the treatment of Advanced Prostate Cancer. By clicking the link below you are declaring and confirming that you are a healthcare professional

You are here

New strategies to target the androgen receptor

Christopher P. Evans

5 New strategies to target the androgen receptor - Christopher P. Evans

With a better understanding of the pathways resulting in castration resistance in prostate cancer, novel therapeutic agents that target the androgen receptor have been developed. Alternatives to new steroidogenesis inhibitors such as galeterone are compounds that block the non-ligand binding domain of the androgen receptor gene. For example EPI-001 that target the N-terminal domain thereby inhibiting gene transcription or VPC-14449 that effects splice variants by binding to the DNA-binding domain. Professor Christopher Evans considers further epigenomic regulation with methylation modifiers such as SD70 or targeting ROR-γ to suppress androgen receptor expression.